Back

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

31 August 2020 (11:00 - 11:10)
Organised by:
Congress Presentation Part of: Novel Approaches to Lipid Lowering Therapy Lipid-Lowering Agents ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Gerald Watts

University of Western Australia, Perth (Australia)

2 More presentations in this session

Presentation thumbnail
RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency
Professor C. Ballantyne (Houston, US)
Abstract Slides Video
Presentation thumbnail
Correlation between different LDL-R mutations and response to ab-PCSK9 therapy in a group of patient with genetic diagnosis of Familial Hypercholesterolemia. Preliminary report.
Doctor A. buonaiuto (Naples, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Novel Approaches to Lipid Lowering Therapy

The Event

Event poster

ESC Congress 2020

31 August 2020 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Where are we now? Decision-making in LDL-C lowering and CV risk
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Congress Presentation
2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources